

# Ethical Issues around the costs of prescription drugs.


US275 Scientific Ethics  
John R. Hoffman  
Arcadia University



1

## Drug Development Challenges

- only a small proportion of interesting chemicals
  - are approved as a new medication
  - time-consuming and costly process



[http://www.pharmfocus.com/strategy/drug\\_development\\_challenges.htm](http://www.pharmfocus.com/strategy/drug_development_challenges.htm)

## Patents provide limited protection for the drug manufacturer.

- issued by patent and trademark office
- patent protection
  - prevents other companies from manufacturing same product.
  - 20 years from date of invention
  - often filed before clinical trials
  - effective protection normally 7 - 12 years



3

# “Innovator” drugs are the first to be available.

- Branded drugs
  - produced by the developer
  - protected by patent
- recover investment costs of drug development
  - drug discovery
  - clinical trials to prove safe and effective
  - estimated at \$800 million for a new drug.



4

## FDA grants exclusive marketing rights to manufacturer upon approval of a new drug.

### Exclusivity lengths

- Orphan Drug (ODE) - 7 years
- New Chemical (NCE)- 5 years
- "Other" Exclusivity - 3 years for a "change" if criteria are met
- Pediatric Exclusivity (PED) - 6 months added to existing Patents/Exclusivity
- Patent Challenge – (PC) – 180 days (this exclusivity is for ANDAs only)



5

## New uses of old drugs

- many drugs have multiple uses
  - new uses require
  - new clinical trials to show that the drug is effective for treatment of a new disease.
- Thalidomide
  - FDA denied approval for use as sedative
    - causes severe birth defects (1957 - 1961)
  - now used to treat multiple myeloma (form of cancer)



6

## Generic firms challenge patents to be able to market prescription drugs.

- if successful in challenge
  - get exclusive copycat rights for six months



7

## Generic drugs

- US Food and Drug Administration (FDA) considers a generic drug to be

- “identical, or bioequivalent, to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use.”



8

## Generic drugs are much cheaper than branded drugs.

- Manufacturer only has to document that the biological activity is the same as the name brand drug
  - does not have to show original research and testing
  - submit abbreviated new drug application (ANDA)
- Generics save retail pharmacy users \$8 - 10 billion per year



9

# Generic drugs are not identical to brand drugs.


- cheaper
- bioequivalent
  - active ingredient the same
  - other ingredients different
- not all drugs available as generic
  - if patent hasn't expired



## Canadian government has established the “Patented Medicine Prices Review Board”


**ensure patented drug prices are not excessive**

- existing drugs cannot increase price by more than the rate of inflation
- most new drugs cannot cost more than similar drugs for the same illness
- new class of drug cannot cost more than the median price for the drug in other countries.



## Drug prices in Canada are cheaper than in the United States.

- Government price control
  - cap on wholesale cost
- Government Health Care plan
  - buy drugs in bulk at a discount
- Lower liability
  - Court awards and damages against health care providers and drug companies much lower than in U.S.




# The United States is the only industrialized country with no price controls on patented medicines.

- Drug companies
  - the presence of price controls limits innovation and development of new drugs.
- Patient advocates
  - government research provides much of the basic science information needed for drug development.



# Purchasing drugs outside of the country.

- No FDA oversight
  - questions of quality assurance
  - counterfeit potential
  - untested substances not available in U.S.
    - safety unknown
    - possible interactions with other drugs



# Accelerated Approval

- surrogate endpoints rather than traditional measures of effectiveness
- used for serious, life-threatening illnesses without satisfactory treatments
- example: most HIV drugs
  - however, continued study post-marketing research
  - FDA can withdraw approval



# FDA Office of Orphan Products Development

- provides incentives for companies to develop products for rare diseases
  - affect fewer than 200,000 people in U.S.
  - or unlikely to recover costs of developing a new drug treatment
  - 350 drugs since 1983,
    - only 10 from 1973 - 1983



16

Assignment

## Assignment

### Drug costs?

Watch the ABC news video. Vital Cancer Drug Shortage at: <http://abcnews.go.com/WNT/video/vital-cancer-drug-shortage-leukemia-cytarabine-chemo-therapy-treatment-13378686>

### In your discussion group:

*Pharmaceutical companies have to balance the goals of producing safe and effective medications while continuing to stay in business by generating a profit. However, the costs of certain vital medications may limit their availability low-patients, production rates limits the supply of medication in circulation, and other medications may not be available across the globe. At a time when illegal drugs can be obtained relatively easily, what can be done to ensure ready access to needed medications?*

17

## Readings

**Follow the pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain.** Henry J. Kaiser Family Foundation. <http://www.kff.org/rxdrugs/upload/follow-the-pill-understanding-the-u-s-commercial-pharmaceutical-supply-chain-report.pdf>

**Obama Tries to Speed Response to Shortages in Vital Medicines.** Harris, G. (10/31/11). New York Times. <http://www.nytimes.com/2011/10/31/health/policy/medicine-shortages-addressed-in-obama-executive-order.html>

**Supply of a Cancer Drug May Run Out Within Weeks.** Harris, G. (02/11/12) New York Times. <http://www.nytimes.com/2012/02/11/health/policy/supply-of-methotrexate-a-cancer-drug-may-run-out-soon.html>



Averroes, Medieval Spanish-Arab philosopher and physician in *Triunfo de Santo Tomás*. Andrea Bonaiuto, 14th century

18

# Any Questions?

Email me at:  
hoffmanj@arcadia.edu



<http://www.vippitbullkennels.com/images/animated-question-mark.gif>